EUREPA V 0.5/0.3MG TABLET 10'S

EUREPA V 0.5/0.3MG TABLET 10'S is typically used to treat mental health conditions such as depression and anxiety. It helps balance chemicals in the brain.

Common side effects may include nausea, dizziness, dry mouth, constipation, and drowsiness. Contact your doctor if these side effects persist or worsen.

Store EUREPA V 0.5/0.3MG TABLET 10'S at room temperature, away from direct sunlight and moisture. Keep it out of reach of children and pets.

EUREPA V 0.5/0.3MG TABLET 10'S is not typically addictive, but it should only be taken as prescribed by your doctor in the specified dosage and duration.

Consult your doctor before taking EUREPA V 0.5/0.3MG TABLET 10'S during pregnancy. It may cause harm to the fetus.

EUREPA V 0.5/0.3MG TABLET 10'S can be taken with or without food, but it is best to take it at the same time each day.

If you miss a dose of EUREPA V 0.5/0.3MG TABLET 10'S, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.

EUREPA V 0.5/0.3MG TABLET 10'S can interact with certain other medications. Inform your doctor about all the medications you are taking.

Symptoms of an overdose of EUREPA V 0.5/0.3MG TABLET 10'S may include excessive drowsiness, confusion, irregular heartbeat, and difficulty breathing.

Avoid drinking alcohol while taking EUREPA V 0.5/0.3MG TABLET 10'S as it can increase the side effects.

It may take a few weeks for EUREPA V 0.5/0.3MG TABLET 10'S to start working. Be patient and continue taking the medication as prescribed by your doctor.

Do not stop taking EUREPA V 0.5/0.3MG TABLET 10'S suddenly. Consult your doctor, who may gradually reduce the dosage.

If you experience any side effects after taking EUREPA V 0.5/0.3MG TABLET 10'S, contact your doctor. They may adjust your dosage or prescribe a different medication.

Consult a doctor before giving EUREPA V 0.5/0.3MG TABLET 10'S to children.

EUREPA V 0.5/0.3MG TABLET 10'S may affect your ability to drive or operate machinery. If you experience side effects such as dizziness or drowsiness, do not drive or operate machinery.

Eurepa V 0.5/0.3 is used for the management of type 2 diabetes mellitus in adults. It helps control blood glucose levels, particularly the rise in sugar that occurs after meals. It is prescribed when lifestyle measures and single-drug therapy are not sufficient to achieve adequate glycaemic control. It is not used for type 1 diabetes or for the treatment of diabetic ketoacidosis.

Eurepa V 0.5/0.3 contains repaglinide and voglibose. Repaglinide stimulates the pancreas to release insulin in response to meals, thereby lowering blood sugar levels after eating. Voglibose acts in the intestine by inhibiting alpha-glucosidase enzymes, which slows the breakdown and absorption of carbohydrates. This results in a more gradual rise in blood glucose after food intake. The combined effect improves postprandial and overall glycaemic control.

No, Eurepa V 0.5/0.3 is not indicated for type 1 diabetes mellitus. Type 1 diabetes is characterised by an absolute deficiency of insulin, and treatment requires insulin injections. Repaglinide requires functioning beta cells in the pancreas to stimulate insulin release, which are absent or severely reduced in type 1 diabetes. This medicine should also not be used for diabetic ketoacidosis, which is a medical emergency requiring insulin and hospital-based care.

Eurepa V 0.5/0.3 is generally taken in relation to meals. If you forget to take a dose and you have not yet started your meal, take it as soon as you remember before eating, if your doctor has advised such timing. If you have already finished the meal or skipped the meal, do not take the missed dose. Do not double the next dose to make up for a missed one, as this may increase the risk of hypoglycaemia. Resume your usual dosing schedule with the next meal and inform your doctor if you frequently miss doses.

Common side effects include gastrointestinal symptoms such as abdominal discomfort, bloating, flatulence, diarrhoea, or constipation, which are often related to voglibose and may improve over time. Hypoglycaemia (low blood sugar) can occur, especially if a meal is delayed, missed, or if you engage in intense physical activity or use other antidiabetic medicines. Symptoms of hypoglycaemia include sweating, tremors, hunger, palpitations, headache, dizziness, and confusion. If these occur, take fast-acting carbohydrates such as glucose tablets or sugary drinks and seek medical advice if symptoms do not improve.

Eurepa V 0.5/0.3 should not be taken by individuals with type 1 diabetes, diabetic ketoacidosis, severe liver impairment, significant gastrointestinal disorders that affect digestion or absorption (such as inflammatory bowel disease, intestinal obstruction, or severe chronic digestive disorders), or known hypersensitivity to repaglinide, voglibose, or any component of the tablet. It should also be avoided in patients with severe systemic illness where oral intake is compromised, unless specifically advised by a specialist.

Yes, Eurepa V 0.5/0.3 can cause hypoglycaemia, mainly due to the insulin-releasing effect of repaglinide. The risk is higher if you skip or delay meals after taking the medicine, consume inadequate carbohydrates, perform unaccustomed strenuous exercise, or use it in combination with other antidiabetic drugs such as insulin or sulfonylureas. To reduce this risk, follow your prescribed meal plan, avoid skipping meals, carry a source of fast-acting sugar, and monitor your blood glucose as advised by your doctor.

Use of Eurepa V 0.5/0.3 in patients with kidney or liver impairment requires caution and individualised assessment. Repaglinide is metabolised in the liver, so patients with hepatic impairment may have higher drug exposure and increased risk of hypoglycaemia. Voglibose acts locally in the gut and is minimally absorbed, but gastrointestinal side effects may be more troublesome in some patients. Your doctor will evaluate your kidney and liver function tests and may adjust therapy, choose alternative medicines, or monitor you more closely. Do not use this medicine without medical supervision if you have known liver or kidney disease.

The safety of repaglinide and voglibose in pregnancy and breastfeeding has not been firmly established. In pregnancy, insulin is generally preferred for blood glucose control because of better-established safety data. Eurepa V 0.5/0.3 should only be used during pregnancy if the potential benefit justifies the potential risk to the mother and fetus, and this decision must be made by a specialist. It is not known whether repaglinide or voglibose is excreted in human breast milk. Therefore, use during breastfeeding is usually not recommended unless clearly needed and under close medical supervision. Always inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.

Alcohol can affect blood glucose levels and may either increase or decrease them unpredictably. When combined with antidiabetic medicines such as Eurepa V 0.5/0.3, alcohol intake can increase the risk of hypoglycaemia or poor glycaemic control. Regular or heavy alcohol consumption may also worsen liver function, which is relevant for repaglinide metabolism. It is advisable to avoid or minimise alcohol intake while on this medicine. If you choose to drink, do so only in moderation, with food, and after discussing it with your doctor.

Eurepa V 0.5/0.3 itself does not directly impair alertness, but hypoglycaemia can significantly affect concentration, reaction time, and judgement. If you experience symptoms of low blood sugar such as dizziness, confusion, blurred vision, or weakness, your ability to drive or operate machinery may be compromised. You should avoid such activities until your blood sugar has normalised and you feel fully recovered. Patients with frequent hypoglycaemic episodes or reduced awareness of hypoglycaemia should discuss driving safety with their doctor.